Cargando…
Liposomal N-acylethanolamine-hydrolyzing acid amidase (NAAA) inhibitor F96 as a new therapy for colitis
Despite numerous advances in the pathological mechanism of inflammatory bowel disease (IBDs), the ideal therapy is still missing. N-Acylethanolamine-hydrolyzing acid amidase (NAAA), a cysteine hydrolase that deactivates fatty acid ethanolamides, has been recognized as a new therapeutic target for IB...
Autores principales: | Xiu, Yangyan, Wang, Kaizhen, Chen, Jingfang, Zhuo, Zhiqiang, Xiu, Yanghui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society of Chemistry
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9056838/ https://www.ncbi.nlm.nih.gov/pubmed/35519029 http://dx.doi.org/10.1039/d0ra05264g |
Ejemplares similares
-
Design and Synthesis of Potent N-Acylethanolamine-hydrolyzing Acid Amidase (NAAA) Inhibitor as Anti-Inflammatory Compounds
por: Li, Yuhang, et al.
Publicado: (2012) -
N‐Acylethanolamine acid amidase (NAAA) is dysregulated in colorectal cancer patients and its inhibition reduces experimental cancer growth
por: Romano, Barbara, et al.
Publicado: (2021) -
Discovery and SAR Evolution of Pyrazole Azabicyclo[3.2.1]octane
Sulfonamides as a Novel Class of Non-Covalent N-Acylethanolamine-Hydrolyzing
Acid Amidase (NAAA) Inhibitors for Oral Administration
por: Di Fruscia, Paolo, et al.
Publicado: (2021) -
Biochemical and Mass Spectrometric Characterization of Human N-Acylethanolamine-Hydrolyzing Acid Amidase Inhibition
por: West, Jay M., et al.
Publicado: (2012) -
Potential analgesic effects of a novel N-acylethanolamine acid amidase inhibitor F96 through PPAR-α
por: Yang, Longhe, et al.
Publicado: (2015)